AbbVie Presents P-III Study (ELEVATE) Results of Qulipta (atogepant) for the Preventive Treatment of Episodic Migraine at AAN 2023
- The P-III study evaluating atogepant (60mg, qd) vs PBO in 315 adult patients. The trial met its 1EPs i.e., patients treated with atogepant (60mg, qd) experienced a decrease of 4.20 days vs 1.85 days in MMDs @12wk
- The trial also met its 2EPs i.e., achievement of ≥50% reduction in MMDs, change from baseline in MMDs, and change from baseline in acute medication use days across 12wks.
- The therapy was well tolerated, and the safety results were consistent with the known safety profile of atogepant. Qulipta (CGRP receptor antagonist) was approved in the US to prevent episodic and chronic migraines in adults. Throughout the year, the company will continue to pursue regulatory submissions for atogepant on all global markets
Ref: AbbVie | Image: AbbVie
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.